Julphar Bangladesh Launched Eltrom (Eltrombopag) in Bangladesh
Through relentless efforts and our devotion to introduce the latest molecules in Bangladesh, Julphar Bangladesh introduced Eltrom (Eltrombopag 25 mg) tablet to treat patients with thrombocytopenia.
Eltrombopag was initially approved by the U.S. Food and Drug Administration on November 20, 2008, for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulin therapy or splenectomy.
Eltrombopag received FDA breakthrough treatment designation in February 2014 for patients with aplastic anemia for which immunosuppression has not been successful. It has been shown to produce a trilineage hematopoesis in some patients with aplastic anemia, resulting increased platelet counts, along with red and white blood cell counts.